Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.695 EUR | +5.28% |
|
+3.35% | +7.62% |
05-20 | Herantis Pharma Submits Clinical Trial Application for A Phase 1B Clinical Trial of Her-096 | CI |
03-06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.62% | 34.8M | |
+17.08% | 122B | |
+18.72% | 114B | |
+19.85% | 25.71B | |
-25.21% | 19.02B | |
-20.21% | 15.83B | |
-19.55% | 15.32B | |
-46.87% | 14.88B | |
+62.31% | 14.82B | |
+5.30% | 14.1B |
- Stock Market
- Equities
- HRTIS Stock
- News Herantis Pharma Oyj
- Transcript : Herantis Pharma Oyj, H2 2022 Earnings Call, Mar 02, 2023